TSE:6806
TSE:6806Electronic

How Investors Are Reacting To Hirose Electric (TSE:6806) Evaluating A Potential Share Buyback Plan

On 25 December 2025, Hirose Electric Co., Ltd. held a board meeting to consider a resolution to repurchase its own shares under Article 156 of the Companies Act, as applied pursuant to Article 165, paragraph 3. This move signals that management is actively weighing capital return options, a decision that can meaningfully influence how investors view the company’s capital allocation discipline. Next, we will examine how this potential share repurchase plan shapes Hirose Electric’s investment...
TSE:8031
TSE:8031Trade Distributors

Is Mitsui’s 2025 Surge Still Supported by Fundamentals After Its Strong Multi Year Rally?

If you have been wondering whether Mitsui's huge run makes it too late to buy or still a potential value play, you are not alone. The stock has climbed 2.2% over the last week, 14.6% in the past month, and is now up 39.0% year to date, with an impressive 44.2% 1 year, 159.3% 3 year, and 473.0% 5 year return that has definitely changed how the market sees its risk and growth profile. Recently, investor attention has focused on Mitsui's strategic investments in energy transition projects and...
TSE:7270
TSE:7270Auto

Subaru (TSE:7270) Valuation Check After Strong Year-to-Date Share Price Rally

Subaru (TSE:7270) has been drifting slightly higher this week, but the real story is how its strong year to date and past 3 months rally stack up against still moderate earnings growth. See our latest analysis for Subaru. That near 24% year to date share price return and solid multi year total shareholder returns suggest momentum is still building as investors steadily price in Subaru's improving earnings base and reduced cyclical risk. If Subaru's move has you watching the auto space more...
TSE:6857
TSE:6857Semiconductor

Is Advantest (TSE:6857) Quietly Repositioning Its Test Platform for the AI Packaging Era?

In December 2025, Advantest and Tokyo Seimitsu announced a collaboration to co-develop a die-level prober for testing advanced AI and high-performance computing devices using complex 2.5D/3D packaging, while Advantest also introduced its T2000 AiR2X next-generation air-cooled test system and later held a board meeting to approve treasury stock disposal for post-issued restricted stock units. This combination of a focused AI/HPC testing partnership and an expanded, more flexible SoC test...
TSE:8986
TSE:8986Residential REITs

Revisiting Daiwa Securities Living Investment (TSE:8986)’s Valuation After Upgraded 2026 Earnings and Distribution Forecasts

Daiwa Securities Living Investment (TSE:8986) just lifted its March 2026 earnings and distribution forecasts, citing stronger than expected gains from property sales, portfolio reshuffling, and new rental housing acquisitions. See our latest analysis for Daiwa Securities Living Investment. The upbeat revision comes on top of an already solid run, with a year to date share price return of 27.19 percent and a 1 year total shareholder return of 36.41 percent. This suggests momentum is still...
TSE:8957
TSE:8957Office REITs

How Investors May Respond To Tokyu REIT (TSE:8957) Extending Debt Maturities And Reducing Leverage

Earlier this year, Tokyu REIT secured a new ¥3,000,000,000 floating-rate, seven-year unsecured loan and used it alongside cash on hand to repay a ¥3,500,000,000 maturing facility, trimming interest-bearing debt by ¥500,000,000 and pushing out its repayment schedule. This refinancing not only lowers financial leverage but also lengthens the debt maturity profile, which can support more resilient funding and risk management for unitholders over the medium term. We’ll now examine how Tokyu...
TSE:4502
TSE:4502Pharmaceuticals

Takeda (TSE:4502) Valuation After Positive Phase 3 Zasocitinib Data Boosts Dermatology Pipeline Potential

Takeda Pharmaceutical (TSE:4502) just delivered encouraging Phase 3 data for its TYK2 inhibitor zasocitinib in moderate to severe plaque psoriasis, and the market is reassessing what this pipeline asset could mean for future growth. See our latest analysis for Takeda Pharmaceutical. Investors seem to be warming back up to Takeda, with the latest TYK2 data arriving after a strong year to date 16.6 percent share price return and a 1 year total shareholder return of 22.7 percent. This suggests...